ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Can Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3148-5798; OpenAlex author ID A5077338429. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper

Papers 2

Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. Co-author DOI 10.3390/ijms22094970 ↗
Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11121869 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Patricia Santofimia‐Castaño · 2 shared papers, 2019–2021 · strength 0.34
- Paper Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. DOI 10.3390/ijms22094970 ↗
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869 ↗
Juan Iovanna · 2 shared papers, 2019–2021 · strength 0.34
- Paper Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. DOI 10.3390/ijms22094970 ↗
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869 ↗
Analía Meilerman Abuelafia · 1 shared paper, 2019 · strength 0.11
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869 ↗
Wenjun Lan · 1 shared paper, 2019 · strength 0.11
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869 ↗
Nicolas Alejandro Fraunhoffer · 1 shared paper, 2019 · strength 0.11
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.